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Production of superoxide (O 2 ·Ϫ ) by NADPH oxidases significantly contributes to the development of heart failure, hypertension, and atherosclerosis (18, 30) . However, factors responsible for activation of NADPH oxidases are not completely understood (22) . Interestingly, mitochondria are the second largest source of vascular O 2 ·Ϫ (3), and mitochondrial dysfunction may be an initiating event in cardiovascular diseases (28) . We, therefore, hypothesized that mitochondrial dysfunction can be involved in the regulation of vascular NADPH oxidases and, thereby, promote vascular disease.
We have recently demonstrated an important role for the Nox2 isoform of NADPH oxidases in cardiovascular disease (23) . Nox2, previously known as gp91
phox , is present in endothelial and phagocytic cells and contributes to blood pressure regulation, inflammation, and cell growth (14, 19, 37, 40) . Nox2 function requires several cytoplasmic factors, such as rac1, p22
phox , p67 phox , and p47 phox (17) . The latter factor p47 phox is of particular importance since its translocation from the cytoplasm and assembly into the Nox2 catalytic complex leads to hundred-fold increase of Nox2 catalytic activity and results in a phenomenon called "oxidative burst" due to robust increase in O 2 ·Ϫ production by phagocytic cells. Under normal unstimulated conditions, basal production of O 2 ·Ϫ by Nox2 is very slow, but treatment of cells with PKC activator PMA results in rapid phosphorylation of p47 phox and assembly of the activated Nox2 complex (41) . PMA stimulation, therefore, represents a convenient model for PKC-dependent Nox2 activation.
Cultured human lymphoblasts are commonly used to study phagocytic NADPH oxidase, since they predominantly express Nox2, but not the Nox1 isoform, and maintain functional mitochondria (31) . Age-associated increased mitochondrial uncoupling and reduced ATP production (4) can be mimicked by mitochondrial inhibitors, such as complex I inhibitor rotenone, mitochondrial proton ionophore CCCP, inhibitors of mitochondrial complex III stigmatellin, or antimycin A (25) . In this work, we studied the effect of mitochondrial inhibitors and an inhibitor of mitochondrial Ca 2ϩ uniporter (12) on PMA-dependent activation of phagocytic NADPH oxidase in human lymphoblasts and human blood (Fig. 1) . Production of O 2 ·Ϫ by phagocytic NADPH oxidase was measured by the extracellular spin probe 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl-trimethylammonium chloride (CAT1H) (10) and electron spin resonance (ESR) (8) . Our data show that decreased calcium uptake by mitochondria and production of mitochondrial reactive oxygen species (ROS) significantly increase phagocytic NADPH oxidase activity.
METHODS
Reagents. Spin probe CAT1H and mitochondria-targeted 1-hydroxy-4-[2-triphenylphosphonio)-acetamido]-2,2,6,6-tetramethylpiperidine (mTH) were purchased from Enzo Life Sciences (Plymouth Meeting, PA). Fura-2 AM was obtained from Invitrogen (Carlsbad, CA). SOD and phorbol 12-myristate 13-acetate (PMA) were acquired from Sigma-Aldrich (St. Louis, MO). All other reagents were obtained from Sigma-Aldrich.
Immortalized cell lines.
In collaboration with the Emory University General Clinical Research Center, human immortalized lymphoblast cell lines were developed from peripheral blood mononuclear cells of human subjects, as described previously (8) . The study was approved by the Institutional Review Board of Emory University and the Atlanta Veterans Affairs Medical Center's Research and Development Committee. All subjects provided informed consent.
To initiate B lymphocyte cultures, lymphocytes were infected with the B95-8 strain of Epstein-Barr Virus (EBV) (33) . After EBVtransformation, B lymphocytes were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine,100 U/ml penicillin, and 100 mg/ml streptomycin, at 37°C in a humid atmosphere saturated with 5% CO2. The medium was changed twice weekly. Cell counts and viability of Ͼ95% (trypan blue stain) were monitored on a daily basis for 2 wk until they were harvested for ESR experiments.
Superoxide measurement with ESR. Superoxide radical was measured by ESR using a Bruker EMX spectrometer (Bruker Biospin) by extracellular CAT1H (1 mM) or mitochondria-targeted mTH (50 M) spin probes (7) . Briefly, cells were washed with PBS and resuspended in Krebs-HEPES buffer (KHB). Subsequently, 1 ϫ 10 6 human lym- Fig. 1 . Measurements of phagocytic NADPH oxidase activity in mouse peripheral blood mononuclear cell (PBMC) and human lymphoblasts by analysis of extracellular O2 ·Ϫ using cell-impermeable spin probe 1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl-trimethylammonium chloride (CAT1H ]i was measured spectrofluorometrically as previously described (36) . Briefly, cells were incubated with fura-2 AM (2 M), and the cell dispersion agent Pluronic F-127 (0.04%) at 37°C in the dark for 30 min. Values of [Ca 2ϩ ]i were obtained by determining maximum fura-2 fluorescence ratio (Rmax) and minimum (Rmin) using 10 M digitonin followed by 30 mM EGTA, as described previously (16) .
Statistics. Experiments were analyzed using the Student-NeumanKeuls post hoc test and ANOVA. P levels Ͻ0.05 were considered significant.
RESULTS

Measurement of phagocytic NADPH oxidase activity by ESR and hydroxylamine spin probes.
We have previously reported that human lymphoblasts produce predominantly extracellular O 2 ·Ϫ because supplementation with extracellular SOD almost completely blocked O 2 ·Ϫ detection by the cell-permeable probe (8) . In this work, we used the cell-impermeable spin probe CAT1H for the detection of extracellular O 2 ·Ϫ as a measure of phagocytic NADPH oxidase activity ( Fig. 1, scheme) . CAT1H rapidly react with O 2 ·Ϫ , producing stable CAT1-nitroxide; therefore, O 2 ·Ϫ production by NADPH oxidase can be measured by accumulation of CAT1 (Fig. 1A) . To validate detection of phagocytic NADPH oxidase activity, we have investigated O 2 ·Ϫ production by mouse peripheral blood mononuclear cell (PBMC) isolated from C57/B6 or gp91 phox KO mice (Fig.  1B) . It was found that PMA stimulation resulted in 10-fold increase in CAT1 accumulation, which was inhibited by supplementation of extracellular SOD. As expected, PMA stimulation did not affect basal O 2 ·Ϫ production by PBMC isolated from gp91 phox KO mice. It was important that supplementation of extracellular SOD inhibited both basal and PMA-stimulated O 2 ·Ϫ production by wild-type PBMC. These data indicate that PMA-stimulated extracellular O 2 ·Ϫ production reflects activation of phagocytic NADPH oxidase, and it can be measured by extracellular spin probe CAT1H (7).
To determine potential contribution of mitochondrial O 2 ·Ϫ in extracellular O 2 ·Ϫ , we have measurements of O 2 ·Ϫ in human lymphoblasts by nitroxide production using extracellular CAT1H probe and mitochondria-targeted mTH probe (Fig.  1C ). Lymphoblasts were acutely treated with NADPH oxidase activator PMA or stimulator of mitochondrial O 2 ·Ϫ antimycin A prior to supplementation of the spin probe. Antimycin A inhibits electron transfer through the mitochondrial respiratory chain, which results in collapse of the mitochondrial membrane potential, overreduction of complex III, and increased O 2 ·Ϫ production on complex III (24) phox with Nox2 to the same extent (35%, data not shown), as was previously reported (29) .
These data suggest that antimycin A-induced mitochondrial uncoupling and production of mitochondrial ROS may stimulate activity of phagocytic NADPH oxidase. To further elucidate the role of mitochondria on stimulation of phagocytic NADPH oxidase, we studied O 2 ·Ϫ production in cells treated with the complex I inhibitor rotenone, mitochondrial proton ionophore CCCP, inhibitors of mitochondrial complex III stigmatellin, or antimycin A (Fig. 3) (25) . We observed that in PMA-treated samples, rotenone significantly increased the activity of phagocytic NADPH oxidase similar to the proton ionophore CCCP. These data suggest that the decrease in mitochondrial membrane potential in the presence of rotenone or CCCP may result in increased activation of phagocytic NADPH oxidase. Interestingly, inhibition of complex III with stigmatellin or antimycin A further increased O 2 ·Ϫ production compared with PMAϩCCCP-treated cells. It is important to note that in contrast to CCCP, treatment with stigmatellin and antimycin A should result in increased production of mitochondrial O 2 ·Ϫ and H 2 O 2 (24) . The difference in the extent of inhibition of NADPH oxidase activity by CCCP compared with complex III inhibitors may implicate mitochondrial ROS in PKC-dependent stimulation of the phagocytic NADPH oxidase.
It has been previously shown that PKC-mediated activation of NADPH oxidase depends on the level of intracellular calcium [Ca 2ϩ ] i (39) . Intracellular calcium is known to be regulated by endoplasmic reticulum, but the role of mitochondria is unknown. Of note, the findings reported above have maintained when experiments were performed in KHB or calcium-free phosphate buffer prepared with chelating resin Chelex-100. Therefore, we tested the hypothesis that inhibition of mitochondrial uptake of calcium would enhance the activity of the phagocytic NADPH oxidase via increase in intracellular calcium [Ca 2ϩ ] i .
Effect of mitochondrial Ca
2ϩ uptake on activation of phagocytic NADPH oxidase. Mitochondria absorb Ca 2ϩ using the mitochondrial calcium uniporter, which can be inhibited by decreased mitochondrial membrane potential or ruthenium red (15) . We studied the role of the calcium uniporter in the activation of the phagocytic NADPH oxidase using lymphoblasts treated with ruthenium red, chelator of intracellular Ca 2ϩ BAPTA-AM, mitochondrial proton ionophore CCCP, and complex III inhibitor antimycin A. We found that ruthenium red did not significantly change the basal O 2 ·Ϫ production in unstimulated cells. Supplementation of PMA-stimulated cells with ruthenium red, however, resulted in robust increase in NADPH oxidase activity compared with cells treated with PMA alone (Fig. 4) . Interestingly, inhibition of the calcium uniporter with CCCP increased NADPH oxidase activity in PMA-stimulated cells similar to ruthenium red-treated cells. Supplementation with antimycin A resulted in higher NADPH oxidase activity compared with ruthenium red-treated cells, which is in line with a possible role for mitochondrial ROS in NADPH oxidase activation (9) . Cotreatment with antimycin A and ruthenium red was not more effective than antimycin A alone, suggesting the inhibition of the calcium uniporter in antimycin A-treated cells. Furthermore, treatment of cells with the chelator of intracellular Ca 2ϩ BAPTA-AM inhibited PMAinduced activation of NADPH oxidase and attenuated the effect of antimycin A on NADPH oxidase activity (Fig. 4) .
These data show that inhibition of Ca 2ϩ uptake by mitochondria significantly increased activity of phagocytic NADPH oxidase, which was attenuated by chelation of intracellular Ca 2ϩ with BAPTA-AM. The role of intracellular Ca in mitochondria-mediated stimulation of NADPH oxidase was further analyzed in Ca 2ϩ -depleted cells. Lymphoblasts were treated with an inhibitor of sarcoplasmic reticulum Ca 2ϩ ATPase, thapsigargin (27) , to deplete Ca 2ϩ stores (35) , and then supplemented with antimycin A, CCCP, and PMA. It was found that depletion of Ca 2ϩ stores attenuated CCCP-and antimycin A-mediated activation of NADPH oxidase in the presence of PMA by 42% and 31%, correspondingly (Fig. 4,TG) .
The above data indicate that inhibition of Ca 2ϩ uptake by mitochondria would increase intracellular Ca 2ϩ . We, therefore, investigated the effects of mitochondrial inhibitors on intracellular Ca 2ϩ levels in human lymphoblasts. Lymphoblasts were loaded with the probe for intracellular Ca 2ϩ fura-2 AM and then treated with mitochondrial inhibitors or a chelator of intracellular Ca 2ϩ BAPTA-AM prior to addition of PMA. We found that treatment of lymphoblasts with antimycin A or CCCP increased the level of intracellular Ca 2ϩ similar to ruthenium red (Fig. 5) ; PMA supplementation further increased intracellular Ca 2ϩ . As expected treatment with the chelator of intracellular Ca 2ϩ BAPTA-AM resulted in significant decrease of [Ca 2ϩ ] i (Fig. 5F ). These data strongly support our hypothesis that inhibition of mitochondrial uptake of Ca 2ϩ stimulates activity of phagocytic NADPH oxidase via an increase in the intracellular Ca 2ϩ level. The above studies show the role for mitochondrial uptake of Ca 2ϩ in activation of the NADPH oxidase in lymphoblasts but do not provide insight into whether the role of mitochondria could be extended to other phagocytic cells. Therefore, we investigated the effect of inhibition of the mitochondrial calcium uniporter on O 2 ·Ϫ production in whole blood.
Mitochondrial function and O 2
·Ϫ production in whole blood. To confirm the role of the mitochondrial calcium uniporter on activation of phagocytic NADPH oxidase in whole blood, we measured O 2 ·Ϫ production in samples with and without PMA stimulation and supplemented with calcium uniporter inhibitor ruthenium red, chelator of intracellular Ca 2ϩ BAPTA-AM, or inhibitor of redox-sensitive K ϩ ATP channel 5-hydroxydecanoate, which may improve mitochondrial function and increase mitochondrial potential (6, 11) . We found that supplementation of ruthenium red resulted in the robust increase of O 2 ·Ϫ production in samples without PMA, while BAPTA-AM inhibited basal O 2 ·Ϫ production (Fig. 6A) . As expected, supplementation of blood with ruthenium red significantly increased PMA-stimulated O 2 ·Ϫ production, while BAPTA-AM attenuated PMA-induced O 2 ·Ϫ production (Fig. 6B) . Interestingly, supplementation with 5-hydroxydecanoate significantly inhibited PMA-stimulated O 2 ·Ϫ production similar to BAPTA-AM, which can be associated with increased activity of the calcium uniporter due to the enhanced mitochondrial membrane potential in 5-hydroxydecanoate-treated cells (11) . These data support the role of the mitochondrial calcium uniporter in the regulation of the phagocytic NADPH oxidase.
DISCUSSION
The present study provides evidence for a mitochondrial role in stimulation of the phagocytic NADPH oxidase. We observed that inhibition of the calcium uniporter with ruthenium red or with complex I or complex III inhibitors resulted in significant increase of intracellular calcium and increased NADPH oxidase activity. The role of mitochondria in stimulation of the phagocytic NADPH oxidase can be summarized in two pathways: 1) uptake of cytoplasmic Ca 2ϩ by the calcium uniporter, and 2) production of mitochondrial ROS (Fig. 7) . Indeed, effects of mitochondrial inhibitors were attenuated with the chelator of intracellular Ca 2ϩ BAPTA-AM both in cultured human lymphoblasts and in whole blood. Furthermore, complex III inhibitors stigmatellin and antimycin A increased production of mitochondrial ROS (24) and inhibited calcium uniporter function, which resulted in more potent stimulation of PMA-induced O 2 ·Ϫ production compared with the inhibition of the calcium uniporter alone by ruthenium red or CCCP. Further analysis confirmed that mitochondria regulate activation of phagocytic NADPH oxidase also in whole blood.
It has been previously reported that activation of phagocytic NADPH oxidase is Ca 2ϩ and H 2 O 2 dependent (13, 34) . Intracellular Ca 2ϩ may stimulate PKC-dependent p47phox phosphorylation and cause Ca 2ϩ -dependent phosphorylation of Nox2 (13) . Interestingly, activation of NADPH oxidase in astrocytes resulted in transient increases in intracellular Ca 2ϩ and caused loss of mitochondrial potential (1, 2) . The mitochondrial response, which consisted of Ca 2ϩ -dependent transient depolarization, was prevented by antioxidants and NADPH oxidase inhibitors, suggesting an upstream role of Nox2-mediated ROS in Ca 2ϩ increase and mitochondrial dysfunction. Indeed, increase of intracellular ROS may lead to elevated intracellular Ca 2ϩ , which may cause mitochondrial Ca 2ϩ overload followed by collapse of mitochondrial potential and apoptosis (25) . Previous works, however, did not study the role of mitochondrial ROS or mitochondrial Ca 2ϩ uptake in the regulation of NA-DPH oxidase activity. In our paper, we were focused on the physiological role of mitochondrial Ca 2ϩ uptake, which attenuates NADPH oxidase activation without mitochondrial depolarization or cell apoptosis.
It has been previously shown that phagocytic NADPH oxidase of human lymphoblasts produces mainly extracellular superoxide (8) . Treatment of these cells with mitochondrial inhibitors did not significantly change the amount of extracellular superoxide in nonstimulated cells (Figs. 2, 3, and 4) . However, inhibition of the calcium uniporter with ruthenium red or treatment with complex I or complex III inhibitors resulted in increased NADPH oxidase activity in the presence of PMA. Antimycin A and stigmatellin may stimulate production of intracellular superoxide and H 2 O 2 (24, 26) . It is, therefore, conceivable that these mitochondrial inhibitors can affect redox regulation of the phagocytic NADPH oxidase. Indeed, we have previously reported that the H 2 O 2 scavenger catalase attenuated PMA-induced activation of the phagocytic NADPH oxidase (8) . Meanwhile, CCCP, which is known to inhibit production of mitochondrial ROS (25) , actually stimulated NADPH oxidase activity. Furthermore, specific inhibition of the Ca 2ϩ uniporter also stimulated NADPH oxidase activity. Similar effects of antimycin A, CCCP, and ruthenium red suggest that output of these mitochondrial inhibitors is primarily due to a decrease in the mitochondrial membrane potential, which is the driving force of the Ca 2ϩ uniporter. Indeed, treatment of cells with antimycin A, CCCP, or ruthenium red resulted in similar increase of intracellular Ca 2ϩ (Fig. 5 ). These data imply that mitochondria play a crucial role in the control of Ca 2ϩ -dependent stimulation of the phagocytic NADPH oxidase. Notably, antimycin A provided significantly higher stimulation of NADPH oxidase compared with CCCP or ruthenium red (Figs. 3 and 4) , which implicates mitochondrial ROS in stimulation of the phagocytic NADPH oxidase. Therefore, we suggest that mitochondria affect phagocytic NADPH oxidase activity via both Ca 2ϩ -dependent and ROS-dependent mechanisms (Fig. 7) .
We suggest that relevance of our findings is not limited to phagocytic cells and phagocytic NADPH oxidase. Indeed, it has been recently shown that overexpression of mitochondrial SOD2 attenuates ANG II-mediated activation of NADPH oxidase in endothelial cells (9) . ANG II mainly activates Nox2 in these cells, which is an analog of phagocytic NADPH oxidase expressed in the vasculature. Interestingly, depletion of SOD2 resulted in overstimulation of NADPH oxidase, and treatment with mitochondria-targeted SOD mimetic mitoTEMPO has reversed the effect of SOD depletion and attenuated activation of NADPH oxidase in endothelial cells. Furthermore, in vivo experiments showed that SOD2 overexpression or mito-TEMPO supplementation has reduced NADPH oxidase activity in vasculature and inhibited vascular O 2 ·Ϫ production. These data imply that mitochondrial ROS stimulate activation of Nox2 and possibly other Nox isoforms, such as Nox1. Interestingly, mitoTEMPO has improved mitochondrial respiration (9) , which may be associated with increased mitochondrial membrane potential. Therefore, additional studies are required to identify the specific role of mitochondrial Ca 2ϩ uptake and ROS in regulation of vascular NADPH oxidase activity.
A growing body of evidence has emerged linking inflammation and aging with the development and progression of cardiovascular diseases (38) . The molecular mechanisms underlying chronic inflammatory conditions, such as hypertension and atherosclerosis during cellular senescence, are not clearly defined. Cellular damage by ROS is a primary driving force for aging and increased activation of redox-regulated transcription factors, such as NF-B, that regulate the expression of proinflammatory genes, has been reported (32) .
It has been previously observed that mitochondrial function declines with age or is altered due to side effects of pharmacological treatments (4) . Our data suggest that mitochondrial impairment can promote activation of phagocytic NADPH oxidase, which may enhance inflammation and ultimately contribute to the development and progression of cardiovascular diseases. Thus, it is conceivable that healthy or younger mitochondria represent an important barrier in stimulation of phagocytic NADPH oxidase, while age-impaired mitochondria may promote NADPH oxidase activation, resulting in enhanced oxidative stress, which would increase inflammation and impair mitochondrial function. Therefore, age-associated mitochondrial dysfunction may play a significant role in the vicious cycle of oxidative stress and inflammation, contributing to the development and progression of cardiovascular diseases.
Perspectives and Significance
It was known that production of superoxide (O 2 ·Ϫ ) by NADPH oxidases may significantly alter mitochondrial function. In this work, we report that mitochondria provide feedforward stimulation of PKC-dependent phagocytic NADPH oxidase. Increased production of mitochondrial ROS and impaired mitochondrial buffering of cytosolic calcium may result in enhanced NADPH oxidase activity and may contribute to the development and progression of cardiovascular diseases.
